Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1221-1225

  Mai, Antonello ^a   Rotili, Dante ^a   Massa, Silvio ^b   Brosch, Gerald ^c   Simonetti, Giovanna ^a   Passariello, Claudio ^a   Palamara, Anna Teresa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antifungal resistance; Fluconazole; Histone deacetylase inhibitors; Trailing

Indexed keywords

FLUCONAZOLE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; URACIL; VORINOSTAT;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG STRUCTURE; EPIGENETICS; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS GROWTH; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PLASMID;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; ENZYME INHIBITORS; FLUCONAZOLE; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

CANDIDA; CANDIDA ALBICANS;

EID: 33846938126     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.028     Document Type: Article

References (56)

1. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Clin. Infect. Dis. 39 (2004) 309
2. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., Denning D.W., Donnelly J.P., Edwards J.E., Erjavec Z., Fiere D., Lortholary O., Maertens J., Meis J.F., Patterson T.F., Ritter J., Selleslag D., Shah P.M., Stevens D.A., and Walsh T.J. Clin. Infect. Dis. 34 (2002) 7
3. Stover B.H., Shulman S.T., Bratcher D.F., Brady M.T., Levine G.L., and Jarvis W.R. Am. J. Infect. Control 29 (2001) 152
4. Wilson L.S., Reyes C.M., Stolpman M., Speckman J., Allen K., and Beney J. Value Health 5 (2002) 26
5. Wisplinghoff H., Seifert H., Tallent S.M., Bischoff T., Wenzel R.P., and Edmond M.B. Pediatr. Infect. Dis. J. 22 (2003) 686
6. Clancy C.J., Staly B., and Nguyen M.H. Antimicrob. Agents Chemother. 50 (2006) 3496
7. Marr K.A., Rustad T.R., Rex J.H., and White T.C. Antimicrob. Agents Chemother. 43 (1999) 1383
8. Revankar S.G., Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Redding S.W., Rinaldi M.G., and Patterson T.F. J. Clin. Microbiol. 36 (1998) 153
9. Rex J.H., Nelson P.W., Paetznick V.L., Lozano-Chiu M., Espinel-Ingroff A., and Anaissie E.J. Antimicrob. Agents Chemother. 42 (1998) 129
10. Ruhnke M., Schmidt-Westhausen A., Engelmann E., and Trautmann M. J. Clin. Microbiol. 34 (1996) 3208
11. Barker K.S., Crisp S., Wiederhold N., Lewis R.E., Bareither B., Eckstein J., Barbuch R., Bard M., and Rogers P.D. J. Antimicrob. Chemother. 54 (2004) 376
12. Mi-Kyung L., Williams L.E., Warnock D.W., and Arthington-Skaggs B.A. J. Antimicrob. Chemother. 53 (2004) 217
13. Calvet H.M., Yeaman M.R., and Filler S.G. Antimicrob. Agents Chemother. 41 (1997) 535
14. Marr K.A., Lyons C.N., Ha K., Rustad T.R., and White T.C. Antimicrob. Agents Chemother. 45 (2001) 52
15. Luger K., Mader A.W., Richmond R.K., Sargent D.F., and Richmond T.J. Nature 389 (1998) 251
16. Urnov F.D., and Wolffe A. Emerg. Ther. Targets 4 (2000) 665
17. Fischle W., Wang Y., and Allis C.D. Curr. Opin. Cell Biol. 15 (2003) 172
18. Akey C.W., and Luger K. Curr. Opin. Struc. Biol. 13 (2003) 6
19. Jones P.A., and Baylin S.B. Nat. Rev. Genet. 3 (2002) 415
20. Momparler R.L. Oncogene 22 (2003) 6479
21. Huang C., Sloan E.A., and Boerkoel C.F. Curr. Opin. Genet. Dev. 13 (2003) 246
22. Verma M., and Srivastava S. Lancet Oncol. 3 (2002) 755
23. Weidle U.H., and Grossmann A. Anticancer Res. 20 (2000) 1471
24. Kramer O.H., Göttlicher M.G., and Heinzel T. Trends Endocrinol. Metab. 12 (2001) 294
25. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Curr. Opin. Oncol. 13 (2001) 477
26. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Nat. Rev. Cancer 1 (2001) 194
27. Vigushin D.M., and Coombes R.C. Anti-Cancer Drugs 13 (2002) 1
28. Johnstone R.W. Nat. Rev. Drug Disc. 1 (2002) 287
29. Kelly W.K., O'Connor O.A., and Marks P.A. Expert Opin. Investig. Drugs 11 (2002) 1695
30. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097
31. Mai A., Massa S., Rotili D., Cerbara I., Valente S., Pezzi R., Simeoni S., and Ragno R. Med. Res. Rev. 25 (2005) 261
32. Srikantha T., Tsai L., Daniels K., Klar A.J.S., and Soll D.R. J. Bacteriol. 183 (2001) 4614
33. Klar A.J.S., Srikantha T., and Soll D.R. Genetics 158 (2001) 919
34. Lamar Smith W., and Edlind T.D. Antimicrob. Agents Chemother. 46 (2002) 3532
35. Massa S., Mai A., Sbardella G., Esposito M., Ragno R., Loidl P., and Brosch G. J. Med. Chem. 44 (2001) 2069
36. Mai A., Massa S., Ragno R., Esposito M., Sbardella G., Nocca G., Scatena R., Jesacher F., Loidl P., and Brosch G. J. Med. Chem. 45 (2002) 1778
37. Mai A., Massa S., Ragno R., Cerbara I., Jesacher F., Loidl P., and Brosch G. J. Med. Chem. 46 (2003) 512
38. Mai A., Massa S., Pezzi R., Rotili D., Loidl P., and Brosch G. J. Med. Chem. 46 (2003) 4826
39. Mai A., Massa S., Cerbara I., Valente S., Ragno R., Bottoni P., Scatena R., Loidl P., and Brosch G. J. Med. Chem. 47 (2004) 1098
40. Ragno R., Mai A., Massa S., Cerbara I., Valente S., Bottoni P., Scatena R., Jesacher F., Loidl P., and Brosch G. J. Med. Chem. 47 (2004) 1351
41. Mai A., Massa S., Pezzi R., Simeoni S., Rotili D., Nebbioso A., Scognamiglio A., Altucci L., Loidl P., and Brosch G. J. Med. Chem. 48 (2005) 3344
42. Mai A., Massa S., Lavu S., Pezzi R., Simeoni S., Ragno R., Mariotti F.R., Chiani F., Camilloni G., and Sinclair D.A. J. Med. Chem. 48 (2005) 7789
43. Mai A., Massa S., Pezzi R., Valente S., Loidl P., and Brosch G. Med. Chem. 1 (2005) 245
44. Mai A., Massa S., Valente S., Simeoni S., Ragno R., Bottoni P., Scatena R., and Brosch G. ChemMedChem 1 (2006) 225
45. Mai A., Massa S., Rotili D., Pezzi R., Bottoni P., Scatena R., Meraner J., and Brosch G. Bioorg. Med. Chem. Lett. 15 (2005) 4656
46. Mai A., Massa S., Rotili D., Simeoni S., Ragno R., Botta G., Nebbioso A., Miceli M., Altucci L., and Brosch G. J. Med. Chem. 49 (2006) 6046
47. Clark J., Munawar Z., and Timms A.W. J. Chem. Soc., Perkin Trans. 2 3 (1972) 233
48. Chemical and physical data of new compounds 3a,b, 4a,b, and 1c,d are reported as Supporting Information.
49. Mori K., and Koseki K. Tetrahedron 44 (1988) 6013
50. Lusser A., Brosch G., Loidl A., Haas H., and Loidl P. Science 277 (1997) 88
51. Kölle D., Brosch G., Lechner T., Pipal A., Helliger W., Taplick J., and Loidl P. Biochemistry 38 (1999) 6769
52. Brosch G., Goralik-Schramel M., and Loidl P. FEBS Lett. 393 (1996) 287
53. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., and Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3003
54. Mai A., Esposito M., Sbardella G., and Massa S. Org. Prep. Proced. Int. 33 (2001) 391
55. 3 CFU/mL in RPMI medium, and an aliquot of 0.1 mL was added to each well of the microdilution plate. The plates were incubated at 35 °C. the MIC end points were read visually following 24 and 48 h of incubation and were defined as the lowest concentration that produced a prominent decrease in turbidity compared with that of the drug-free growth control. In addition to visual end point readings, the optical density of each microplate well was measured with a microplate spectrophotometer set at 405 nm. Spectrophotometric MICs were calculated based on the density of the growth control and were the lowest drug concentrations that resulted in a 50% reduction in growth compared with that of the drug-free growth control.
56. Development of FLU resistance: cultures of C. albicans were passed in increasing concentrations of fluconazole (up to 64 μg/mL) and fluconazole (up to 64 μg/mL) plus HDAC inhibitors (4 μg/mL). Specifically, the cultures were grown at 30 °C in YPD (1% yeast extract, 2% peptone, and 2% dextrose) in an environmental shaking incubator, and cells were passed when cultures were turbid (1-3 days between passages). At each passage, a 1 mL aliquot of the suspension was mixed with 0.5 mL of 50% glycerol, and the mixture was frozen at -70 °C for antifungal susceptibility testing as described above.